VOX ROYALTY CORP. (VOXR): Financial results for Q3 2026

VOX ROYALTY CORP. (VOXR) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.5 VOX ROYALTY REPORTS Q3 2026 RESULTS AND DECLARES QUARTERLY DIVIDEND DENVER – November 11, 2026 – Vox Royalty Corp. (NASDAQ: VOXR ) (TSX: VOXR ) (“ Vox ” or the “ Company ”), a returns-focused mining royalty and streaming company, is pleased to announce its operating

Original reporting
Published Nov 12, 2026, 1:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 1:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$VOXR
Bullish
medium confidence
Mentioned
$VOXR
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 6-K
Decision brief

The 30-second read

$VOXRBullishMed
01

Why it matters

The Q3 2026 results show improved profitability and a new dividend, which could attract income‑seeking investors and support the stock.

02

Market read

First‑time earnings disclosure for a small‑cap junior royalty company; may cause modest price movement.

03

What to watch

The company's exposure to copper and upcoming capital expenditures could temper upside if metal prices weaken.

Relevance 7/10Novelty 7/10Timing: after‑hours release

Background

VOX Royalty Corp. (NASDAQ: VOXR) is a mining royalty and streaming company focused on gold and industrial metals.

Company-level read

Ticker impact

$VOXRBullishMedium confidence
Context

Q3 2026 earnings release reporting net income of $2.2 M, record royalty revenue and a quarterly dividend of $0.015 per share.

Expected impact

potential modest upside as investors price in stronger earnings and dividend payout

Evidence & confidence

The company posted higher net income and cash flow versus the prior year and announced a dividend, which typically supports the stock price in the short term.

Market effects

Positive earnings may lift other junior gold royalty and streaming stocks as the sector shows resilience.

North American junior mining sector could see modest buying pressure.

Limited to the niche royalty/streaming segment; no broad market impact.

Counterpoint

If the earnings growth is driven by one‑off royalty acquisitions, the sustainability of earnings may be questioned.

Key entities

  • Vox Royalty Corp.

    NASDAQ‑listed mining royalty and streaming firm reporting Q3 2026 results.

  • Kyle Floyd

    CEO of Vox Royalty Corp., quoted on the earnings release.

Related articles

$VOXRMed

Vox Royalty expects production growth from over 10 assets by 2029

Vox Royalty Corp. (VOXR) updated investors on three key assets and projected production growth from over 10 royalties and streams by 2029. Kanmantoo mine reported increased copper production and reserves. Sugar Zone gold mine expects restart in 2027, while Los Filos mine is restarting with growth capital. The company holds over 70 royalties and streams, with 11 currently producing.

$VOXRMed

Vox Royalty Provides Update & Timeline for Assets Entering Production

Vox Royalty Corp. (VOXR) updated investors on its key gold and copper assets, including Kanmantoo, Sugar Zone, and Los Filos. The company expects over 10 assets to start or restart production between Q4 2026 and H1 2029, potentially doubling its producing asset count. CEO Kyle Floyd highlighted growth in production and reserves, with no additional development capital required from Vox.

$VOXRMed

VOX ROYALTY CORP. (VOXR): Financial results for Q2 2026

VOX ROYALTY CORP. (VOXR) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.5 VOX ROYALTY REPORTS Q2 2026 RESULTS AND DECLARES QUARTERLY DIVIDEND DENVER – August 12, 2026 – Vox Royalty Corp. (NASDAQ: VOXR ) (TSX: VOXR ) (“ Vox ” or the “ Company ”), a returns-focused mining royalty and streaming company, is pleased to announce its operating an

$KYTXMed

Kyverna Therapeutics 3Q 2026: EPS ($0.68) — 10-Q Summary

Kyverna Therapeutics reported a 14% wider net loss YoY in 3Q 2026, with total operating expenses rising 11%. R&D expenses fell 11%, while general and administrative expenses increased 92%. The company completed a rolling BLA submission for miv-cel in SPS and expects to finish patient enrollment in a Phase 3 trial by mid-2027.